Brief: XBiotech's Results From Phase 2 Atopic Dermatitis Study Suggest New Drug To Treat Skin Disease
12/12/2018 13:34
Dec 12 (Reuters) - XBiotech Inc XBIT.O :
* XBIOTECH’S RESULTS FROM PHASE 2 ATOPIC DERMATITIS STUDY
SUGGEST
NEW DRUG TO TREAT SKIN DISEASE
* XBIOTECH INC - STUDY MET ALL PRIMARY AND SECONDARY
ENDPOINTS
* XBIOTECH INC - STATISTICALLY SIGNIFICANT IMPROVEMENT WAS
SEEN
FOR ALL EFFICACY ENDPOINTS IN HIGH DOSE GROUP OF STUDY
Source text for Eikon: ID:nGNE5yXChq
Further company coverage: XBIT.O
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke